Acute Myeloid Leukemia

Detailed Overview

AML is the most common acute leukemia in adults. It is characterized by immense genetic and molecular heterogeneity. The leukemic myeloblasts accumulate in the marrow, leading to critical deficiencies in mature erythrocytes, granulocytes, and platelets. AML can arise de novo or secondary to antecedent hematologic disorders (like myelodysplastic syndromes) or prior leukemogenic therapies (radiation or chemotherapy). The World Health Organization (WHO) classifies AML based heavily on recurrent genetic abnormalities (e.g., t(15;17) in Acute Promyelocytic Leukemia, FLT3 mutations, NPM1 mutations), which dictate the disease's prognosis and increasingly guide targeted therapeutic strategies.

Epidemiology & Demographics

Predominantly a disease of older adults. Median age at diagnosis is 68 years. Incidence is approximately 4.3 per 100,000 adults in the US, slightly higher in men than women.

Etiological Mechanism

Most cases arise de novo with acquired somatic mutations. Known triggers include ionizing radiation, benzene exposure, prior chemotherapy (alkylators, topoisomerase II inhibitors), and progression from antecedent clonal disorders (MDS, myeloproliferative neoplasms).

Primary Causes

Acquired somatic mutations (NPM1, FLT3, IDH1/2)

Therapy-related (prior chemo/radiation)

Evolution from Myelodysplastic Syndrome (MDS)

• Advanced Age: Risk increases significantly after age 60 due to accumulation of somatic mutations.
• Chemical Exposure: Chronic exposure to benzene (found in certain industrial solvents and cigarette smoke).
• Genetic Disorders: Fanconi anemia, Bloom syndrome, and Down syndrome carry higher risks.

Pathogenesis requires at least two classes of mutations. Class I mutations (e.g., FLT3-ITD, c-KIT) confer a proliferative and survival advantage to the clone. Class II mutations (e.g., RUNX1-RUNX1T1, CEBPA) impair normal myeloid differentiation. The resulting maturation block causes an accumulation of non-functional myeloblasts. These blasts expand within the bone marrow space, physically and chemically suppressing normal erythropoiesis, myelopoiesis, and megakaryopoiesis, resulting in peripheral blood cytopenias. Some blasts may invade extramedullary tissues, causing leukemic cutis or gingival hypertrophy (particularly in monocytic subtypes).

Characteristic Clinical Presentation

• Severe Fatigue: Secondary to profound anemia and high metabolic demand of the tumor.
• Spontaneous Bleeding: Epistaxis, gingival bleeding, or menorrhagia due to severe thrombocytopenia or disseminated intravascular coagulation (DIC).
• Unexplained Fevers/Infections: Bacterial or fungal infections resulting from absolute neutropenia.

Physical Examination Signs

• Gingival Hyperplasia
• Leukemia Cutis
• Pallor and Petechiae

• Disseminated Intravascular Coagulation (DIC): Particularly highly associated with Acute Promyelocytic Leukemia (APL), presenting with severe bleeding and thrombosis.
• Leukostasis: Sludging of blasts in microvasculature (when WBC > 100,000/mcL), causing hypoxia, stroke, or pulmonary infiltrates.

Diagnostic Criteria & Guidelines

Diagnosis requires ≥ 20% myeloblasts in the bone marrow or peripheral blood. Alternatively, the presence of specific recurrent genetic abnormalities (e.g., t(15;17), t(8;21), inv(16)) defines AML regardless of the blast percentage.

Differential Diagnosis

• Acute Lymphoblastic Leukemia (ALL)
• Myelodysplastic Syndromes (MDS)
• Severe Vitamin B12/Folate Deficiency (can cause severe pancytopenia)

Laboratory Tests & Biomarkers

• Peripheral Blood Smear: Presence of myeloblasts, often containing Auer rods (distinctive needle-like eosinophilic cytoplasmic inclusions).
• Coagulation Panel: Elevated PT/aPTT, decreased fibrinogen, elevated D-dimer if DIC is present.
• Flow Cytometry: Blasts express myeloid antigens: CD13+, CD33+, CD34+, CD117+, MPO+.

Imaging Modalities & Findings

• Chest CT: May show opportunistic fungal pneumonia (e.g., Aspergillus 'halo sign') in neutropenic patients.
• Brain MRI: Indicated if neurologic symptoms are present to evaluate for chloromas (myeloid sarcomas) or leukemic meningitis.

• Untreated
  Newly diagnosed disease requiring urgent induction chemotherapy.
• Complete Remission (CR)
  Bone marrow blasts < 5%, absence of extramedullary disease, and recovery of peripheral counts (ANC > 1000, Plt > 100K).
• Relapsed/Refractory
  Return of disease after CR or failure to achieve CR with initial therapy.

Second-Line & Adjunctive Therapy

For older/unfit patients: Venetoclax (BCL-2 inhibitor) 400 mg PO daily + Azacitidine (hypomethylating agent) 75 mg/m2 SC/IV for 7 days every 28 days.

Surgical & Procedural Management

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is the definitive post-remission therapy (consolidation) for patients with intermediate or high-risk cytogenetics to provide a graft-versus-leukemia effect.

Recommended Lifestyle Changes

• Rigorous neutropenic precautions and dental hygiene.
• Strict adherence to prophylactic antimicrobials (e.g., Posaconazole, Acyclovir) during treatment.

Patient Counseling & Advice

Discuss the intensive nature of the "7+3" regimen requiring a 3-4 week hospital stay. Counsel extensively on the high risk of life-threatening infections and the potential need for stem cell transplantation.

Follow-Up & Monitoring Schedule

Frequent bone marrow aspirations (typically around day 14 and day 28 post-induction) to assess for remission and measurable residual disease (MRD).

Preventive Strategies

No standard screening or prevention. Minimize occupational exposure to benzenes and unnecessary radiation.

Highly dependent on age and molecular genetics. Favorable risk (e.g., inv(16), t(8;21), isolated NPM1 mutation) has a >60% cure rate. Adverse risk (e.g., complex karyotype, TP53 mutation) has a <20% 5-year survival, heavily relying on stem cell transplant success.